Combination Treatment For Diabetes Using An Egf Receptor Ligand And A Gastrin Compound

Abstract

The invention relates to compositions and methods for the prevention and/or treatment of a condition and/or disease, in particular diabetes, comprising a therapeutically effective amount of at least one EGF receptor ligand and at least one gastrin compound. The combination of at least one EGF receptor ligand and at least one gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases including but not limited to diabetes and related diseases and disorders. Combinations of at least one EGF receptor ligand and at least one gastrin compound can be selected to provide unexpectedly additive, complementary or synergistic effects. Particular subjects that can be treated with the compositions and methods of the invention are subjects with baseline HbA1c levels greater than about 5%, 6%, or 7%, and/or subjects receiving a glucose lowering agent and/or an insulin sensitivity enhancer, in particular a metformin with or without a thiazolidinedione.


Claims

Download Citation


Sign in to the Lens

Feedback